Researchers have long sought a definitive biomarker for mental health disorders. Specifically, **Neuropeptide Y levels** have garnered attention due to their purported role in stress resilience and emotional regulation. However, a recent study published in Acta Neuropsychiatrica suggests that the relationship between these levels and clinical depression may be more complex than previously thought. The research indicates that age, rather than a psychiatric diagnosis, serves as the primary driver of peripheral NPY concentrations.

The Danish PRISME cohort provided the clinical data for this investigation. Scientists examined 77 adults with a current diagnosis of major depressive disorder (MDD) alongside 77 matched healthy controls. By utilizing a commercial ELISA kit, the laboratory measured plasma NPY (p-NPY) concentrations. To ensure statistical accuracy, the researchers applied log-transformation to the values and utilized a general linear model to account for age, sex, and body mass index (BMI).

Interpreting Fluctuations in Neuropeptide Y levels with Age

The results revealed no significant difference in **Neuropeptide Y levels** between the MDD group and the control group (p = 0.785). Furthermore, factors such as sex and BMI did not influence the p-NPY concentrations. In contrast, age emerged as a robust predictor of peripheral NPY (β = 0.38, p < 0.001). This finding suggests that NPY naturally increases as individuals grow older. Therefore, clinicians must exercise caution when interpreting p-NPY as a specific marker for depression.

These findings have significant implications for geriatric psychiatry. Because NPY levels rise with age, using them as a standalone diagnostic tool for depression in elderly populations could lead to misinterpretation. Additionally, the lack of a cross-sectional link to MDD in this study emphasizes the need for larger, longitudinal studies to clarify if NPY changes precede or follow depressive episodes. Consequently, the search for a reliable peripheral biomarker continues.

Is Neuropeptide Y a reliable biomarker for depression?

Current research, including the Danish PRISME cohort study, suggests that peripheral Neuropeptide Y levels do not differ significantly between individuals with major depressive disorder and healthy controls. Therefore, it is not currently considered a reliable diagnostic biomarker for MDD.

How does age affect Neuropeptide Y concentrations?

Studies indicate that Neuropeptide Y levels increase as a person ages. This age-dependent rise is a significant predictor of NPY concentrations, regardless of a person's mental health status or body mass index.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

Dahlaki MH et al. Age-Dependent Increase in Peripheral Neuropeptide Y with No Cross-Sectional Link to Depression. Acta Neuropsychiatr. 2026 May 08. doi: 10.1017/neu.2026.10084. PMID: 42098897.

Ang S, et al. The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023. PMC. 2025.

Gaurav et al. Cross talk about the role of Neuropeptide Y in CNS disorders and diseases. Neuropeptides. 2023.